SCHEMBL31376136

SCHEMBL31376136

O=C(OC1CCOC1)c1ccc(C(=O)c2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 3/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47
HTR3A P46098 1/20 0.47
HTR3D Q70Z44 1/20 0.47
HTR3C Q8WXA8 1/20 0.47
APOBEC3A P31941 1/20 0.46
APOBEC3G Q9HC16 1/20 0.46
SCN1A P35498 1/20 0.45
SCN2A Q99250 1/20 0.45
SCN3A Q9NY46 1/20 0.45
GAA P10253 1/20 0.44
ELANE P08246 1/20 0.43
HPGD P15428 1/20 0.43
CTSL P07711 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22101385 0.94 CHRNA7 (0.54) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL21886707 0.94 CHRNA7 (0.54) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL14461205 0.94 CHRNA7 (0.54) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL13369465 0.85 CHRNA7 (0.51) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL12614061 0.85 CHRNA7 (0.51) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL5185766 0.84 KMT2A (0.59) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL18670620 0.82 SCN1A (0.57) MEN1KMT2ASCN1ASCN2ASCN3A
SCHEMBL28339381 0.81 CHRNA7 (0.56) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL4730582 0.78 MEN1 (0.56) CHRNA7MEN1KMT2AHTR3EHTR3B
SCHEMBL11637921 0.78 CHRNA7 (0.53) CHRNA7MEN1KMT2AHTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250032440-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS NATIONAL INSTITUTES OF HEALTH 2025-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250032440-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS NLN, PSEN2, PSEN1 CHRNA7 361/4885MEN1 4452/4885KMT2A 3549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.